Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Antidiabetic Effects of the Senolytic Agent Dasatinib
Omid Salaami, Chia‐Ling Kuo, Matthew T. Drake, et al.
Mayo Clinic Proceedings (2021) Vol. 96, Iss. 12, pp. 3021-3029
Open Access | Times Cited: 19

Showing 19 citing articles:

Cellular senescence and senolytics: the path to the clinic
Selim Chaib, Tamar Tchkonia, James L. Kirkland
Nature Medicine (2022) Vol. 28, Iss. 8, pp. 1556-1568
Open Access | Times Cited: 627
Endothelial senescence in vascular diseases: current understanding and future opportunities in senotherapeutics
Yeaeun Han, Sung Young Kim
Experimental & Molecular Medicine (2023) Vol. 55, Iss. 1, pp. 1-12
Open Access | Times Cited: 102
Adipose tissue as a linchpin of organismal ageing
Tammy Nguyen, Silvia Corvera
Nature Metabolism (2024) Vol. 6, Iss. 5, pp. 793-807
Closed Access | Times Cited: 19
Senolytics: Eliminating Senescent Cells and Alleviating Intervertebral Disc Degeneration
Yuhao Wu, Shiwei Shen, Yifeng Shi, et al.
Frontiers in Bioengineering and Biotechnology (2022) Vol. 10
Open Access | Times Cited: 31
Senolytic drugs dasatinib and quercetin combined with Carboplatin or Olaparib reduced the peritoneal and adipose tissue metastasis of ovarian cancer
Lian Wang, Bing Xiong, Wei Lü, et al.
Biomedicine & Pharmacotherapy (2024) Vol. 174, pp. 116474-116474
Open Access | Times Cited: 8
Glycaemic abnormalities induced by small molecule tryosine kinase inhibitors: a review
Takudzwa Mugiya, Mamosheledi Mothibe, Andile Khathi, et al.
Frontiers in Pharmacology (2024) Vol. 15
Open Access | Times Cited: 5
Potential Clinical Implications of Senotherapies for Cardiovascular Disease
Masayoshi Suda, Goro Katsuumi, Tamar Tchkonia, et al.
Circulation Journal (2023) Vol. 88, Iss. 3, pp. 277-284
Open Access | Times Cited: 12
Cellular senescence and frailty: a comprehensive insight into the causal links
Serena Marcozzi, Giorgia Bigossi, Maria Giuliani, et al.
GeroScience (2023) Vol. 45, Iss. 6, pp. 3267-3305
Open Access | Times Cited: 7
Cellular Senescence and Senolytic Agents: Recent Updates on Their Role and Applications
Lokesh Chandrakar, Ramesh Ambatwar, Gopal L. Khatik
Current Topics in Medicinal Chemistry (2023) Vol. 24, Iss. 2, pp. 157-178
Closed Access | Times Cited: 4
Diazoxide-Responsive Hypoglycemia in a Child Receiving Dasatinib for Treatment of B-Cell Acute Lymphoblastic Leukemia
M. Berra, Juliana Biro, Himala Kashmiri, et al.
JCEM Case Reports (2024) Vol. 2, Iss. 12
Open Access | Times Cited: 1
Kinase inhibitors for cancer alter metabolism, blood glucose, and insulin
Brittany M. Duggan, Daniel M. Marko, Raveen Muzaffar, et al.
Journal of Endocrinology (2022)
Open Access | Times Cited: 7
The Direct and Indirect Effects of Tyrosine Kinase Inhibitors on the Cardiovascular System in Chronic Myeloid Leukemia
Alessandro Nanni Costa, Raimondo Pittorru, Giovanni Caocci, et al.
Hemato (2023) Vol. 4, Iss. 3, pp. 207-226
Open Access | Times Cited: 2
Age-related disease: Diabetes
Allyson K. Palmer, James L. Kirkland
Aging (2024), pp. 175-193
Closed Access
Drug repurposing for metabolic disorders: Scientific, technological and economic issues
Nhat-Le Bui, Duc-Anh Hoang, Quang-Anh Ho, et al.
Progress in molecular biology and translational science (2024), pp. 321-336
Closed Access
Sorafenib decreases glycemia by impairing hepatic glucose metabolism
Jingjing Ma, Fang Sui, Yan Liu, et al.
Endocrine (2022) Vol. 78, Iss. 3, pp. 446-457
Closed Access | Times Cited: 2
Are off-target effects of imatinib the key to improving beta-cell function in diabetes?
Nils Welsh
Upsala Journal of Medical Sciences (2022) Vol. 127
Open Access | Times Cited: 1
Homoharringtonine, a novel senotherapeutic, mitigates diet- and age-associated obesity and insulin resistance
Hoon‐Ki Sung, Eok-Cheon Kim, Han-Byul Jung, et al.
Research Square (Research Square) (2023)
Open Access
Neue Ansätze zur Regeneration der insulinproduzierenden β-Zelle
Elke Schlüssel, Heiko Lickert
Deleted Journal (2022) Vol. 18, Iss. 7, pp. 792-801
Closed Access
Long-term durability of improved glycemic control in type 2 diabetes mellitus treated with dasatinib, a second-generation tyrosine kinase inhibitor, for chronic myeloid leukemia: A report of two cases
Atsunori Kashiwagi
Journal of Clinical Images and Medical Case Reports (2022) Vol. 3, Iss. 9
Open Access
Page 1

Scroll to top